Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
UTRECHT, The Netherlands, Nov. 10, 2016 -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday, November 17, 2016 at 11:20 PM GMT at the Waldorf Hilton in London, UK.
A live webcast of the Jefferies presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Contacts: Merus N.V. Shelley Margetson – [email protected] +31 (0)30 253 8800 Argot Partners Kimberly Minarovich – [email protected] 1-212-600-1902
